Suresh K. Mittal

Suresh K. Mittal

Purdue University, USA

Title: Broadly protective infl uenza vaccines for pandemic preparedness


"Suresh K. Mittal completed his Ph.D. in 1989 from Cambridge University and postdoctoral studies from McMaster University. He joined Purdue University College of Veterinary Medicine in 1995 and is currently serving as a Professor of Virology and Director of Graduate Training in the Department of Comparative Pathobiology. He has published more than 70 papers in peer-reviewed journals and holds six patents."


"Recurrent outbreaks of H5, H7 and H9 avian influenza viruses in domestic poultry accompanied by their occasional transmission to humans have highlighted the public health threat posed by these viruses. Newer vaccine approaches for pandemic preparedness against these viruses are needed given the limitations of vaccines currently approved for H5N1 viruses in terms of their production timelines and the ability to induce protective immune responses in the absence of adjuvants. In this study, we evaluated the feasibility of an adenovirus (AdV)-based multivalent vaccine approach for pandemic preparedness against H5, H7 and H9 avian influenza viruses in a mouse model. Replication-defective AdV vectors expressing hemagglutinin (HA) from different subtypes and nucleoprotein (NP) from one subtype induced high levels of humoral and cellular immune responses and conferred protection against virus replication following challenge with H5, H7 and H9 avian influenza virus subtypes. Inclusion of HA from the 2009 H1N1 pandemic virus in the vaccine formulation further broadened the vaccine coverage. Significantly high levels of HA stalk-specific antibodies were observed following immunization with the multivalent vaccine. Inclusion of NP into the multivalent HA vaccine formulation resulted in the induction of CD8 T cell responses. These results suggest that a multivalent vaccine strategy may provide reasonable protection in the event of a pandemic caused by an H5, H7, or H9 avian influenza virus before a strain-matched vaccine can be produced."

Speaker Presentations

Speaker PDFs